Mirtazapin Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Sandoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on noradrenergic and serotonergic pathways to treat depressive conditions.

- Major depressive disorder: reduces depressive symptoms and improves mood. - Depression with insomnia: helps alleviate sleep disturbances associated with depression. - Depression with anxiety: mitigates anxiety symptoms that coexist with depressive episodes.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior - Serotonin syndrome when combined with other serotonergic agents - Severe hypersensitivity reactions (rash, angioedema) - Hepatic dysfunction or jaundice - Unexplained bleeding or bruising

Before initiating therapy, clinicians should consider several safety factors.

- Hepatic function: assess liver enzymes in patients with existing liver disease. - Suicidal ideation: monitor closely during the first weeks of treatment, especially in younger adults. - Elderly patients: start at lower doses due to increased sensitivity to sedation. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Concomitant CNS depressants: use cautiously as additive sedation may occur. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Potent CNS depressants (e.g., benzodiazepines, alcohol): may cause excessive sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampicin): may alter mirtazapine plasma levels. - Antihypertensive drugs: additive hypotensive effect may occur. - Alcohol: can enhance sedative properties and impair cognition.